{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:57:24Z","timestamp":1776794244484,"version":"3.51.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This survey was conducted to identify factors that influence how patients with neovascular age-related macular degeneration (nAMD) deal with their disease and information that are considered useful from a patient\u2019s point of view.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 5035 patients with nAMD living in Germany were interviewed via internet-based cross-sectional survey, where the following information was collected: personal data, disease awareness, and patients\u2019 needs. In addition, a Quality of Life questionnaire (SF-12v2) could be completed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of the 5035 participants, more males than females participated (55% vs 45%), and most participants were in the age groups 76 to 85\u00a0years (37%) and 66 to 75\u00a0years (35%). Seventy-three percent of patients rated their understanding of the disease as at least sufficient, and more than two-thirds of the patients (68%) were aware that their disease needs to be controlled on a regular basis and treated on an \u201cas needed\u201d basis. Regarding potential risk factors for AMD, most participants were aware of age (89%), but only 39% of hereditary load and 33% of smoking as evidence-based risk factors, indicating a need for further information. The doctor remains the major source of information (93%), with internet (29%), brochures (14%), opticians (13%), or patient support groups (4%) with only limited contribution. Distance to the treatment center was identified as one of the factors, which had the greatest influence on patients\u2019 compliance. A \u201ctreat as needed\u201d regime turned out to be the preferred control and treatment schedule in contrast to a \u201cfixed appointment\u201d every 4\u00a0weeks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This internet-based survey appears to be representative for nAMD patients. To increase patients\u2019 compliance, proximity to the treatment center and a \u201ctreat as needed\u201d regime turned out to be important factors as well as patients\u2019 awareness of their disease. In this regard, the reported desire for more information indicates that patients\u2019 knowledge still needs to be improved. Our results will help to further optimize patient care and patient-oriented information.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00417-022-05678-7","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T10:03:59Z","timestamp":1652436239000},"page":"3241-3253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["nAMD: optimization of patient care and patient-oriented information with the help of an internet-based survey"],"prefix":"10.1007","volume":"260","author":[{"given":"Anke","family":"Schmid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicitas","family":"Bucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Liczenczias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Maslanka Figueroa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0331-1109","authenticated-orcid":false,"given":"Hansj\u00fcrgen","family":"Agostini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"5678_CR1","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s00417-014-2591-9","volume":"252","author":"CA Korb","year":"2014","unstructured":"Korb CA, Kottler UB, Wolfram C et al (2014) Prevalence of age-related macular degeneration in a large European cohort: results from the population-based Gutenberg Health Study. Graefes Arch Clin Exp Ophthalmol 252:1403\u20131411. https:\/\/doi.org\/10.1007\/s00417-014-2591-9","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5678_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3238\/arztebl.2020.0513","volume":"117","author":"A Stahl","year":"2020","unstructured":"Stahl A (2020) The diagnosis and treatment of age-related macular degeneration. Dtsch Arztebl Int 117:513\u2013520. https:\/\/doi.org\/10.3238\/arztebl.2020.0513","journal-title":"Dtsch Arztebl Int"},{"key":"5678_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ajo.2011.10.016","volume":"153","author":"SB Bloch","year":"2012","unstructured":"Bloch SB, Larsen M, Munch IC (2012) Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 153:209-213.e2. https:\/\/doi.org\/10.1016\/j.ajo.2011.10.016","journal-title":"Am J Ophthalmol"},{"key":"5678_CR4","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS et al (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120:2292\u20132299. https:\/\/doi.org\/10.1016\/j.ophtha.2013.03.046","journal-title":"Ophthalmology"},{"key":"5678_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00347-015-0099-2","volume":"113","author":"F Ziemssen","year":"2016","unstructured":"Ziemssen F, Bertelmann T, Hufenbach U et al (2016) Delayed treatment initiation of more than 2 weeks. Relevance for possible gain of visual acuity after anti-VEGF therapy under real life conditions (interim analysis of the prospective OCEAN study). Ophthalmologe 113:143\u2013151. https:\/\/doi.org\/10.1007\/s00347-015-0099-2","journal-title":"Ophthalmologe"},{"key":"5678_CR6","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/bjophthalmol-2015-308166","volume":"100","author":"FG Holz","year":"2016","unstructured":"Holz FG, Tadayoni R, Beatty S et al (2016) Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol 100:1623\u20131628. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-308166","journal-title":"Br J Ophthalmol"},{"key":"5678_CR7","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444. https:\/\/doi.org\/10.1056\/NEJMoa062655","journal-title":"N Engl J Med"},{"key":"5678_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57-65.e5. https:\/\/doi.org\/10.1016\/j.ophtha.2008.10.018","journal-title":"Ophthalmology"},{"key":"5678_CR9","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"5678_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/OPTH.S151611","volume":"12","author":"C Ehlken","year":"2018","unstructured":"Ehlken C, Helms M, B\u00f6hringer D et al (2018) Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol 12:13\u201320. https:\/\/doi.org\/10.2147\/OPTH.S151611","journal-title":"Clin Ophthalmol"},{"key":"5678_CR11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S et al (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99:220\u2013226. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305327","journal-title":"Br J Ophthalmol"},{"key":"5678_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ophtha.2018.08.023","volume":"126","author":"V Nguyen","year":"2019","unstructured":"Nguyen V, Daien V, Guymer R et al (2019) Projection of long-term visual acuity outcomes based on initial treatment response in neovascular age-related macular degeneration. Ophthalmology 126:64\u201374. https:\/\/doi.org\/10.1016\/j.ophtha.2018.08.023","journal-title":"Ophthalmology"},{"key":"5678_CR13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jfo.2014.11.015","volume":"38","author":"E Boulanger-Scemama","year":"2015","unstructured":"Boulanger-Scemama E, Querques G, About F et al (2015) Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting. J Fr Ophtalmol 38:620\u2013627. https:\/\/doi.org\/10.1016\/j.jfo.2014.11.015","journal-title":"J Fr Ophtalmol"},{"key":"5678_CR14","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00417-012-2177-3","volume":"251","author":"KM Droege","year":"2013","unstructured":"Droege KM, Muether PS, Hermann MM et al (2013) Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Arch Clin Exp Ophthalmol 251:1281\u20131284. https:\/\/doi.org\/10.1007\/s00417-012-2177-3","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5678_CR15","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1167\/iovs.15-16444","volume":"56","author":"AC Thompson","year":"2015","unstructured":"Thompson AC, Thompson MO, Young DL et al (2015) Barriers to follow-up and strategies to improve adherence to appointments for care of chronic eye diseases. Invest Ophthalmol Vis Sci 56:4324\u20134331. https:\/\/doi.org\/10.1167\/iovs.15-16444","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5678_CR16","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00417-020-04798-2","volume":"258","author":"C Ehlken","year":"2020","unstructured":"Ehlken C, Ziemssen F, Eter N et al (2020) Systematic review: non-adherence and non-persistence in intravitreal treatment. Graefes Arch Clin Exp Ophthalmol 258:2077\u20132090. https:\/\/doi.org\/10.1007\/s00417-020-04798-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5678_CR17","unstructured":"National Institute for Health and Care Excellence (2018) Age-related macular degeneration: diagnosis and management - NICE Guideline, No. 82. NICE, London"},{"key":"5678_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1080\/13548506.2014.936886","volume":"20","author":"J Boyle","year":"2015","unstructured":"Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C (2015) Experiences of patients undergoing anti-VEGF treatment for neovascular age-related macular degeneration: a systematic review. Psychol Health Med 20:296\u2013310. https:\/\/doi.org\/10.1080\/13548506.2014.936886","journal-title":"Psychol Health Med"},{"key":"5678_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4274\/tjo.28003","volume":"47","author":"O Polat","year":"2017","unstructured":"Polat O, \u0130nan S, \u00d6zcan S et al (2017) Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration. Turk J Ophthalmol 47:205\u2013210. https:\/\/doi.org\/10.4274\/tjo.28003","journal-title":"Turk J Ophthalmol"},{"key":"5678_CR20","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s00347-006-1418-4","volume":"103","author":"WF Schrader","year":"2006","unstructured":"Schrader WF (2006) Age-related macular degeneration: a socioeconomic time bomb in our aging society. Ophthalmologe 103:742\u2013748. https:\/\/doi.org\/10.1007\/s00347-006-1418-4","journal-title":"Ophthalmologe"},{"key":"5678_CR21","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.1007\/978-94-007-0753-5_2698","volume-title":"Encyclopedia of Quality of Life and Well-Being Research","author":"D Turner-Bowker","year":"2014","unstructured":"Turner-Bowker D, Hogue SJ (2014) Short Form 12 Health Survey (SF-12). In: Michalos AC (ed) Encyclopedia of Quality of Life and Well-Being Research. Springer, Netherlands, pp 5954\u20135957"},{"key":"5678_CR22","unstructured":"Ware J (1994) SF-12v2\u00aeHealth Survey\u00a9. Medical Outcomes Trust (MOT) , Health Assessment Lab (HAL) and Quality Metric Incorporated. All rights reserved. SF-12\u00ae is a registered trademark of medical Outcomes Trust. (SF-12v2\u00ae Health Survey Standard, Germany (German))"},{"key":"5678_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","volume":"34","author":"J Ware","year":"1996","unstructured":"Ware J, Kosinski M, Keller SD (1996) A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220\u2013233. https:\/\/doi.org\/10.1097\/00005650-199603000-00003","journal-title":"Med Care"},{"key":"5678_CR24","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1007\/s00417-017-3739-1","volume":"255","author":"S M\u00fcller","year":"2017","unstructured":"M\u00fcller S, Ehlken C, Bauer-Steinhusen U et al (2017) Treatment of age-related neovascular macular degeneration: the patient\u2019s perspective. Graefes Arch Clin Exp Ophthalmol 255:2237\u20132246. https:\/\/doi.org\/10.1007\/s00417-017-3739-1","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5678_CR25","unstructured":"Statistisches Bundesamt (Destatis) (2019) Sozialleistungen - Angaben zur Krankenversicherung (Ergebnisse des Mikrozensus), Fachserie 13 Reihe 1.1, Tabelle 2. https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Gesundheit\/Gesundheitszustand-Relevantes-Verhalten\/Publikationen\/Downloads-Gesundheitszustand\/krankenversicherung-mikrozensus-2130110199004.html. Accessed 11 Mar 2022"},{"key":"5678_CR26","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1097\/IAE.0b013e3182018df6","volume":"32","author":"R Rauch","year":"2012","unstructured":"Rauch R, Weingessel B, Maca SM, Vecsei-Marlovits PV (2012) Time to first treatment: the significance of early treatment of exudative age-related macular degeneration. Retina 32:1260\u20131264. https:\/\/doi.org\/10.1097\/IAE.0b013e3182018df6","journal-title":"Retina"},{"key":"5678_CR27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000239236","volume":"224","author":"R Schalnus","year":"2010","unstructured":"Schalnus R, Meyer CH, Kuhli-Hattenbach C, L\u00fcchtenberg M (2010) Time between symptom onset and assessment in age-related macular degeneration with subfoveal choroidal neovascularization. Ophthalmologica 224:176\u2013182. https:\/\/doi.org\/10.1159\/000239236","journal-title":"Ophthalmologica"},{"key":"5678_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10792-017-0492-8","volume":"38","author":"TP Marakis","year":"2018","unstructured":"Marakis TP, Koutsandrea C, Chatzistefanou KI, Tountas Y (2018) Treatment satisfaction of patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents. Int Ophthalmol 38:565\u2013576. https:\/\/doi.org\/10.1007\/s10792-017-0492-8","journal-title":"Int Ophthalmol"},{"key":"5678_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1471-2415-10-31","volume":"10","author":"U Chakravarthy","year":"2010","unstructured":"Chakravarthy U, Wong TY, Fletcher A et al (2010) Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol 10:31. https:\/\/doi.org\/10.1186\/1471-2415-10-31","journal-title":"BMC Ophthalmol"},{"key":"5678_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2019.100825","volume":"76","author":"MP Rozing","year":"2020","unstructured":"Rozing MP, Durhuus JA, Krogh Nielsen M et al (2020) Age-related macular degeneration: a two-level model hypothesis. Prog Retin Eye Res 76:100825. https:\/\/doi.org\/10.1016\/j.preteyeres.2019.100825","journal-title":"Prog Retin Eye Res"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05678-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-022-05678-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05678-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T05:06:43Z","timestamp":1663218403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-022-05678-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["5678"],"URL":"https:\/\/doi.org\/10.1007\/s00417-022-05678-7","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"assertion":[{"value":"13 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from Ethics committee of University of Freiburg\/positive vote 03. March 2020. German clinical trials Register ID: DRKS00021031.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained electronically from all participants completing the survey.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Erika Liczenczias, Sara Maslanka Figueroa, and Bettina M\u00fcller are employees of Novartis Pharma GmbH. Hansj\u00fcrgen Agostini received institutional funds from Novartis for scientific research. Felicitas Bucher received institutional funds from Roche for scientific research and from Bayer and Novartis for lectures. Anke Schmid declares not to have any conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}